Single-Dose Pharmacokinetics of Sodium Ferric Gluconate Complex in Iron-Deficient Subjects

Pharmacotherapy

Volumn 24, Issue 5 I, 2004, Pages 574-583

  Seligman, Paul A ^a   Dahl, Naomi V ^b   Strobos, Jur ^c   Kimko, Hui C ^d   Schleicher, Rhoda B ^a   Jones, Michael ^b   Ducharme, Murray P ^e  

^a UNIVERSITY OF COLORADO   (United States)

^b Watson Laboratories Inc   (United States)

^c R and D Laboratories Inc   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e MDS Inc   (Canada)

Author keywords

Ferrlecit; Iron; Pharmacokinetics; Sodium ferric gluconate complex

Indexed keywords

FERRIC GLUCONATE; IRON; IRON DEXTRAN; TRANSFERRIN;

ADULT; ARTICLE; BLOOD SAMPLING; BONE MARROW; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INFUSION; FEMALE; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON TRANSPORT; MALE; RANDOMIZED CONTROLLED TRIAL; RETICULOENDOTHELIAL SYSTEM; SINGLE DRUG DOSE; URINALYSIS;

ADULT; BIOLOGICAL AVAILABILITY; FEMALE; FERRIC COMPOUNDS; FERRITINS; HALF-LIFE; HUMANS; IRON; MALE;

EID: 2342505763     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.6.574.34750     Document Type: Article

References (28)

1. National Kidney Foundation-Kidney Disease Outcomes Quality Initiative. Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37:S182-238.
2. Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med 1977;87:710-13.
3. Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997;48:34-40.
4. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995;25:433-9.
5. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999;33:464-70.
6. Michael B, Coyne DW, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002;61:1830-9.
7. Coyne DW, Adkinson NF, Nissenson AR, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003;63:217-24.
8. Watson Pharma, Inc. Ferrlecit (sodium ferric gluconate complex in sucrose injection) package insert. Morristown, NJ; 2001.
9. Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG, for the Ferrlecit Publication Committee. Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long term safety. Nephrol Dial Transplant, in press.
10. Folkert V, Michael B, Agarwal R, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher dose (250 mg) administration. Am J Kidney Dis 2003;41:651-7.
11. Jain AK, Bastani B. Safety profile of a high dose ferric gluconate in patients with severe chronic renal insufficiency. J Nephrol 2002;15:681-3.
12. Javier AM. Weekly administration of high-dose sodium ferric gluconate is safe and effective in peritoneal dialysis patients. Nephrol Nurs J 2002;29:183-6.
13. Henderson PA, Hillman RS. Characteristics of iron dextran utilization in man. Blood 1969;34:357-75.
14. Zanen AL, Adriaansen HJ, van Bommel EF, Posthuma R, Th de Jong GM. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit) in haemodialysis patients. Nephrol Dial Transplant 1996;11:820-4.
15. Seligman PA, Schleicher RB. Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 1999;45:898-901.
16. Persijn JP, Van Der Slik W, Riethorst A. Determination of serum iron and latent iron binding capacity (LIBC). Clin Chem Acta 1971;35:91-8.
17. Sigma Diagnostics. Iron and total iron binding capacity. Procedure 565. St. Louis, MO, 2000.
18. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, Inc., 1982.
19. D'Argenio DZ, Schumitzky A. ADAPT II user's guide (release 4). Biomedical Simulations Resource, University of Southern California, Los Angeles, 1997.
20. Hillman RS. Hematopoietic agents. In: Hardman JG, Gilman AG, Limbird LW, eds. Goodman & Gilman's the pharmacological basis of therapeutics, 9th ed. Montreal: McGraw-Hill, 1996:1311-40.
21. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980;243:1726-31.
22. American Regent Laboratories, Inc. Venofer (iron sucrose) package insert. Shirley, NY, 2003.
23. Danielson BG, Salmonson T, Derendorf H, Geisser P. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 1996;46:615-21.
24. Goldenberg H, Scheiber-Mojdehkar B, Brunner-Doepper L, Kryzer I. Iron from parenteral preparations alters non-transferrin iron uptake and the RNA-binding activity of iron-regulatory protein in rat hepatocytes and human hepatoma cells. Internet Association for Biomedical Sciences 2000. Sixth Internet World Congress for biomedical sciences, February 14-25, 2000. Available from www.uclm.es/inabis2000.
25. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000;15:1827-34.
26. Robotham JL, Lietman PS. Acute iron poisoning: a review. Am J Dis Child 1980;134:875-9.
27. Linder MC, Schaffer KJ, Hazegh-Azam M, Zhou CY, Tran TN, Nagel GM. Serum ferritin: does it differ from tissue ferritin? J Gastroenterol Hepatol 1996;11:1033-6.
28. Tran TN, Eubanks SK, Schaffer KJ, Zhou CY, Linder MC. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 1997;90:4979-86.